CIK 0000818033
- Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 942875566
- Phone
- +1 858-251-4400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-04-30 | Quart Barry D Chief Executive Officer | Other acquisition | +806 | $18.43 | $15K | 90,081 |
| 2019-04-30 | MANHARD KIMBERLY Executive VP, Drug Development | Other acquisition | +1,109 | $18.43 | $20K | 1,109 |
| 2018-12-15 | Rosen Robert President | Grant or award · Employee Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2018-12-15 | Quart Barry D Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2018-12-15 | MANHARD KIMBERLY Executive VP, Drug Development | Grant or award · Employee Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2018-12-15 | HOFFMAN ROBERT CFO & SVP, Finance | Grant or award · Employee Stock Option (Right to Buy) | +71,000 | 71,000 | ||
| 2018-12-15 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +17,000 | 17,000 | ||
| 2018-12-15 | POYHONEN JOHN Director | Grant or award · Stock Option (Right to Buy) | +19,500 | 19,500 | ||
| 2018-12-15 | POYHONEN JOHN Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2018-12-15 | Johnson Craig A Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2018-12-15 | TANG KEVIN C Director | Grant or award · Stock Option (right to buy) | +17,000 | 17,000 | ||
| 2018-11-02 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −494 | $30.62 | $15K | 0 |
| 2018-10-31 | MANHARD KIMBERLY Executive VP, Drug Development | Other acquisition | +494 | $23.60 | $12K | 494 |
| 2018-10-01 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion | +6,000 | $13.00 | $78K | 6,000 |
| 2018-10-01 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −6,000 | $32.07 | $192K | 0 |
| 2018-10-01 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion · Employee Stock Option (Right to Buy) | −6,000 | 82,416 | ||
| 2018-09-14 | Quart Barry D Chief Executive Officer | Exercise or conversion | +19,675 | $7.20 | $142K | 89,275 |
| 2018-09-14 | Quart Barry D Chief Executive Officer | Exercise or conversion · Employee Stock Option (Right to Buy) | −19,675 | 710,601 | ||
| 2018-09-12 | TANG KEVIN C Director | Sale | −2,695,000 | $35.75 | $96.3M | 5,830,215 |
| 2018-07-02 | MANHARD KIMBERLY Executive VP, Drug Development | Exercise or conversion | +6,000 | $13.00 | $78K | 6,000 |
Page 31 of 38 · 746 trades